JSB Market Research: Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 - PowerPoint PPT Presentation

About This Presentation
Title:

JSB Market Research: Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Description:

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. – PowerPoint PPT presentation

Number of Views:61

less

Transcript and Presenter's Notes

Title: JSB Market Research: Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022


1
Tarceva (Non-Small Cell Lung Cancer) - Forecast
and Market Analysis to 2022
To buy this Report Visit http//www.jsbmarketresea
rch.com
2
Summary
  • Non-Small Cell Lung Cancer (NSCLC) is the
    most common lung cancer, and the second-most
    common cancer in men and women. Historically, the
    treatment paradigm has centered around
    chemotherapy. However, the launch of targeted
    therapies for patients with specific biomarkers
    has begun to fragment the NSCLC treatment
    landscape into smaller niche patient populations.
    Over the forecast period, this trend will
    continue with the launch of multiple new drugs in
    several new drug classes to address the high
    unmet need among NSCLC patients, and provide new
    treatment options for previously underserved
    populations. Launch of premium-priced drug
    candidates combined with increasing incident
    cases of the disease will be major drivers of
    growth in the major markets.

3
Reason To Buy This Report
  • Understand and capitalize by identifying products
    that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding
    the changing competitive landscape for NSCLC
  • Effectively plan your MA and partnership
    strategies by identifying drugs with the most
    promising sales potential
  • Make more informed business decisions from
    insightful and in-depth analysis of Tarceva
    performance
  • Obtain sales forecast for Tarceva from 2012-2022
    in top nine countries (the US, France, Germany,
    Italy, Spain, the UK, Japan, India and China)
  • To know more about this report click here
  • http//www.jsbmarketresearch.com/healthcare-
    medical/r-Tarceva-Non-Small-Cell-Lung-Cancer-Forec
    ast-and-Market-Analysis-to-2022-114976

4
Tarceva (Non-Small Cell Lung Cancer)
Disease Overview
Disease Management
Tarceva (erlotinib hydrochloride)
Competitive Assessment
5
Related Market Research Report
  • RiceBran Technologies (RIBT) - Financial and
    Strategic SWOT Analysis Review
  • BioLineRx, Ltd. (BLRX) - Financial and Strategic
    SWOT Analysis Review
  • Comvita Limited (CVT) - Financial and Strategic
    SWOT Analysis Review
  • Yiaco Medical Co. (YIACO) - Financial and
    Strategic SWOT Analysis Review

6
About JSB Market Research
  • Jsbmarketresearch.com is an online repository of
    an extensive collection of market research
    reports available online. This online portal
    contains high-quality reports with
    well-researched and high-quality content on a
    wide range of industries. These market research
    reports help us give a detailed insight into new
    opportunities in the industry, prevailing market
    trends, competitor analysis and future prospects.
  • JSBs reports are developed by the domain experts
    and publishers under a closely observed
    surveillance of industry specialists. Therefore,
    the researched data is well researched, well-
    organized and matching up to the best standards
    in the industry. Also JSBs database consists of
    detailed insights of the leading players in the
    global market, products and trends.

7
Contact Us
  • Support General Inquiries
  • Mail support_at_jsbmarketresearch.com
    1-800-986-4312
  • Billing Support
  • Mail billing_at_jsbmarketresearch.com
    91 22 412 366 50
  • Website http//www.jsbmarketresearch.com
Write a Comment
User Comments (0)
About PowerShow.com